It’s the latest move in the race by drug companies to corner more of the highly-lucrative obesity drug market.

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to ...

Alnylam Pharmaceuticals has announced a $250 million investment to expand its manufacturing facility in Massachusetts. The ...

The state accuses the pharmaceutical giant of colluding with other insulin makers to hike the price by more than 1,000% over ...

The lawsuit alleges insulin can cost Eli Lilly just a few dollars to produce, while some consumers are charged hundreds of ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Indiana is joining other states accusing the pharmaceutical giant of inflating drug costs by more than 1,000%.